Cargando…
TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study
The long-term survival of patients with hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT) is poor. Systemic therapy, transcatheter arterial chemoembolization (TACE), and hepatic artery infusion chemotherapy are widely used in HCC patients with PVTT. This study aims to explore th...
Autores principales: | Yuan, Yichuan, He, Wei, Yang, Zhiwen, Qiu, Jiliang, Huang, Zhenkun, Shi, Yunxing, Lin, Zhu, Zheng, Yun, Chen, Minshan, Lau, Wan Yee, Li, Binkui, Yuan, Yunfei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389515/ https://www.ncbi.nlm.nih.gov/pubmed/37026861 http://dx.doi.org/10.1097/JS9.0000000000000256 |
Ejemplares similares
-
Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?
por: Ge, Naijian, et al.
Publicado: (2023) -
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis
por: Zhang, XiuPing, et al.
Publicado: (2017) -
TACE Plus Lenvatinib Versus TACE Plus Sorafenib for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Prospective Cohort Study
por: Yang, Biao, et al.
Publicado: (2021) -
Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study
por: Qiu, Zhiyu, et al.
Publicado: (2021) -
HAIC versus TACE for patients with unresectable hepatocellular carcinoma: A systematic review and meta-analysis
por: Liu, Junguo, et al.
Publicado: (2022)